Ketamine News and Research

RSS

Black patients more likely to be chemically sedated at the EDs than their white counterparts

Black patients presenting at Emergency Departments (EDs) across the country with psychiatric complaints are 63 percent more likely to be chemically sedated than their white counterparts.

7 Apr 2023

Common anesthesia drug could help reduce pressure inside the skull of children with TBI

A common anesthesia drug could be beneficial in reducing pressure inside the skull of children with traumatic brain injuries (TBI), according to a study published in Critical Care Medicine.

31 Mar 2023

A shot of liver-produced hormone sobers up drunk mice

A hormone called fibroblast growth factor 21 (FGF21) protects mice against ethanol-induced loss of balance and righting reflex, according to a study publishing on March 7 in the journal Cell Metabolism.

7 Mar 2023

Ketamine appears to hold promise in treating cocaine-use disorders

As cocaine use continues to climb across the United States, scientists have struggled to develop an effective pharmacological approach to treat the devastating disorder.

20 Feb 2023

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.

17 Feb 2023

The therapeutic effects and safety of psychedelics

Psychedelics are reported to have rapid-onset and long-lasting therapeutic benefits after a single or few doses.

14 Dec 2022

Study shows how ketamine administration starkly changes neuronal activity patterns in the brain

Ketamine, an established anesthetic and increasingly popular antidepressant, dramatically reorganizes activity in the brain, as if a switch had been flipped on its active circuits, according to a new study by Penn Medicine researchers.

1 Dec 2022

Early mobility contributes to higher survival rates for COVID-19 patients receiving ECMO

A Texas cardiac subspecialty hospital with seven years of experience with extracorporeal membrane oxygenation (ECMO) changed its treatment paradigm during the COVID-19 pandemic, finding that progressive mobility and a more aggressive application of rehabilitation therapies contributed to significantly higher survival rates for its patients with COVID-19 receiving ECMO.

15 Nov 2022

Researchers unravel neurobiological mechanisms impacted by early life adversity

Using cutting edge molecular techniques in rodent models, researchers are dissecting the neurobiological mechanisms impacted by early life adversity.

9 Nov 2022

New compound triggers the same anti-depressant action as rapidly acting psychedelic drugs

While illegal for recreational use, psychedelic drugs are showing great promise as treatments for severe depression and anxiety, as well as alcohol addiction and other conditions.

28 Sep 2022

Low-dose ketamine is safe and effective to treat children with ADNP syndrome, study suggests

Results of a small, but unique research study, led by researchers from the Seaver Autism Center for Research and Treatment at Mount Sinai and published online in Human Genetics and Genomic Advances, suggest that low-dose ketamine is generally safe, well-tolerated and effective to treat clinical symptoms in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.

6 Sep 2022

Antiviral activity of favipiravir against Zika and SARS-CoV-2 in cynomolgus macaques

A new study determines the antiviral efficacy of favipiravir against ZIKV and SARS-CoV-2 infections.

4 Sep 2022

Therapeutic use of ketamine may be safe, study suggests

Commonly used in medicine as an anesthetic, ketamine is also increasingly prescribed to relieve depressive symptoms. This very fast-acting psychotropic drug is particularly indicated for the treatment of patients resistant to conventional antidepressants.

4 Aug 2022

PCORI approves $258 million funding to support 26 new health care-related studies

The Patient-Centered Outcomes Research Institute has approved funding awards totaling $258 million to support 26 new research studies.

26 Jul 2022

$50 million PCORI funding approved for studies focused on treating suicidal depression and bipolar depression

Research teams at Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, have been approved for more than $50 million in funding awards by the Patient-Centered Outcomes Research Institute for studies focused on treating two important mental health conditions.

26 Jul 2022

Study identifies how ketamine works as a rapid antidepressant

Ketamine is the speedster of antidepressants, working within hours compared to more common antidepressants that can take several weeks. But ketamine can only be given for a limited amount of time because of its many side effects.

1 Jun 2022

Ketamine uses a previously unknown pathway to produce an antidepressant effect, study finds

For the 280 million people suffering from depression globally, relief cannot come fast enough. Monoaminergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) take weeks to months to take effect and do not work for more than one in three patients.

26 May 2022